What's in Eisai Korea Inc.'s pipeline?

Eisai Korea Inc. has 5 drugs in our index: 5 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Eisai Korea Inc.'s portfolio?

Top competitors by shared drug class: Mario Negri Institute for Pharmacological Research, Janssen Korea, Ltd., Korea, Johnson & Johnson Taiwan Ltd, Ministry of Health and Sports, Myanmar, Odense University Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/eisai-korea-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Eisai Korea Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eisai Korea Inc. pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Aricept	Aricept	marketed		Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon	Neuroscience
Safinamide Mesilate	Safinamide Mesilate	marketed
zonisamide high dose group	zonisamide high dose group	marketed	Sulfonamide anticonvulsant	Voltage-gated sodium channels, T-type calcium channels, GABA enhancement	Neurology
Pariet	Pariet	marketed			Other
zonisamide low dose group	zonisamide low dose group	marketed	Anticonvulsant / Antiepileptic agent	Sodium channels, calcium channels, carbonic anhydrase	Neurology

Therapeutic area mix

Neurology · 2
Neuroscience · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Mario Negri Institute for Pharmacological Research · 2 shared drug classes
Janssen Korea, Ltd., Korea · 1 shared drug class
Johnson & Johnson Taiwan Ltd · 1 shared drug class
Ministry of Health and Sports, Myanmar · 1 shared drug class
Odense University Hospital · 1 shared drug class
Rose Research Center, LLC · 1 shared drug class
UCB BIOSCIENCES GmbH · 1 shared drug class
University Hospitals Cleveland Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Eisai Korea Inc.:

Cite this brief

Drug Landscape (2026). Eisai Korea Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/eisai-korea-inc. Accessed 2026-05-16.